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Obesity, the most common nutritional disorder in industrial countries, is associ-
ated with increased cardiovascular mortality and morbidity. Nevertheless, the mole-
cular basis linking obesity with cardiovascular disturbances have not yet been fully
clarified. Recent advances in the biology of adipose tissue indicate that it is not sim-
ply an energy storage organ, but also a secretory organ, producing a variety of bioac-
tive substances, including leptin and adiponectin, that may influence the function as
well as the structural integrity of the cardiovascular system. Leptin, besides being a
satiety signal for the central nervous system and to be related to insulin and glucose
metabolism, may also play an important role in regulating vascular tone because of
the widespread distribution of functional receptors in the vascular cells. On the other
hand, the more recently discovered protein, adiponectin, seems to playa protective
role in experimental models of vascular injury, in probable relation to its ability to
suppress the attachment of monocytes to endothelial cells, which is an early event in
the atherosclerotic process. There is already considerable evidence linking altered
production of some adipocyte hormones with the cardiovascular complications of
obesity. Therefore, the knowledge of alterations in the endocrine function of adipose
tissue may help to further understand the high cardiovascular risk associated with
obesity.
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Obesity-associated
cardiovascular diseases
Diabetes mellitus, hyperlipidemia,
hypertension and atherosclerosis have
been recently defined as typical lifestyle-
related diseases. A common background
of these diseases is overnutrition and its
consequence, obesity. An individual with
a body mass index (BMI) greater than 30
kg/rrr' is four times more likely to suffer
from nearly all of the common cardiovas-
cular diseases (stroke, coronary artery dis-
ease, congestive heart failure, cardiomy-
opathy, and possibly arrhythmia/sudden
death) than an individual with a BMI of 25
kg/rrr' or less (3, 21). So, obesity is an
independent risk factor of cardiovascular
diseases (CVD). Previous epidemiological
studies of obesity have documented a
modest association of obesity and risk of
CVD, especially in younger age groups.
Weight gain during young adult life may
be one of the most important determi-
nants of cardiovascular risk factors. It is
now well accepted that inflammation is a
major component of atherosclerosis.
Moreover, adipose tissue is now recog-
nized as a source of inflammatory media-
tors, with production of cytokines such as
tumor necrosis factor (TNF)-u and inter-
leukin (lL)-6 (59). It appears likely, that
the relationship between obesity, insulin
resistance and atherosclerosis may
depend, at least in part, on the increased
production and release of these inflamma-
tory mediators from adipose tissue. Obe-
sity is a prothrombotic state, in part due
to a secondary effect of insulin resistance;
this is a contributing factor to elevated
risk of coronary heart disease and stroke
(43). Pulmonary thromboembolic disease
also occurs at higher rates in the obese,
probably because of venous stasis (30).
As it has been resumed, the effects of
obesity on cardiovascular health and dis-
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ease are many, but one of the most pro-
found is hypertension. Epidemiological
studies suggest that up to 50% of obese
individuals have concomitant hyperten-
sion (38). Studies in humans show that
weight gain raises blood pressure and that
weight loss reduces blood pressure in
both normotensive and hypertensive
patients (49). Obesity also appears to
change the normal circadian variation of
blood pressure. In a recent study, it has
been described that up to 70% of obese-
hypertensive subjects failed to show an
appropriate fall in both systolic anddias-
tolic pressures during sleep (74). The
hemodynamic profile of obese subjects is
characterised by high intravascular vol-
ume, high cardiac output, and high
peripheral resistance (27, 48). Because
heart rate remains unchanged, the increase
in cardiac output in response to the ele-
vated metabolic requirements and
expanded intravascular volume occurs
chiefly through increased stroke volume.
Moreover, cellular metabolism of cations
and other molecules may be altered in
obesity and lead to changes in vascular
responsiveness (62). Among these mole-
cules, insulin has been shown to be a
vasodilator that regulates peripheral vas-
cular resistance. Insulin not only inhibits
voltage-gated Caz+ influx, but also stimu-
lates glucose transport and phosphoryla-
tion of glucose to glucose-6-phosphate,
which further activates Ca2+-ATPase
transcription and increases cellular Caz+
efflux. Both actions result in a net decrease
in intracellular Caz+ and, therefore,
decreased vascular resistance. These
effects are blunted in obesity due to
insulin resistance, leading to increased
vascular resistance (78). Besides, obesity
is often accompanied with structural
changes in peripheral resistance vessels (8,
62).
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Adipose tissue as an endocrine organ
A main characteristic of obesity is the
exaggerated augmentation of adipose tis-
sue. Recent advances in the biology of adi-
pose tissue have revealed that it is not sim-
ply an energy storage organ (22, 29). The
adipocyte must not be considered as an
inert depot for storing fuel as lipid, to be
released only during times of hardship
such as fasting or starvation. In fact, it also
secretes hormones in response to specific
extracellular stimuli or changes in meta-
bolic status (63). Most of these hormones
act in an autocrine/paracrine manner to
regulate adipocyte metabolism; upon
secretion into the blood stream, they act
as endocrine signals at multiple distant
sites to regulate energy homeostasis (23).
So~e of these varieties of biologically
active molecules perform diverse func-
tions, but seem to share some structural
properties of cytokines. They have been
conceptualised collectively as "adipocy-
tokines/adipokines" (69). Some of these
proteins are inflammatory cytokines,
some play a role in lipid metabolism,
while others are involved in vascular
homeostasis or the complement system
(Table I). Thus, adipose cells playa more
dynamic role than previously recognised
in physiological mechanisms (50). In the
present review, the role of adiponectin, a
novel adipose-specific gene product, and
leptin, the obese (ob) gene product, will be
discussed.
Adiponectin
Adiponectin, the gene product of the
adipose most-abundant gene transcript 1
(apMl) gene, is an adipocyte-derived plas-
ma protein identified in 1995 from the
human cDNA project targeting on adi-
pose tissue. Adiponectin is a 244-amino
acid protein with high structural hornolo-
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gy to collagen VIII, X and complement
Cl q (44, 55). This protein was also identi-
fied independently by three other
groups using different approaches, and
was named as gelatin-binding protein
(GBP28) (51), adipocyte complement-
related protein of 30 kDa (Acrp30) (64) or
!,dipoQ (35). Acrp30 and AdipoQ were
Isolated from differentiated adipocytes
and they are the mouse counterpart of
adiponectin. It is expressed specifically in
white adipose tissue and exists abundant-
ly in the plasma, approximately 0.01% of
total plasma protein (5, 34). Its secretion is
modulated by insulin, pointing to the pos-
sibility that the expression is regulated by
the nutritional state (7, 76). Clinically,
plasma adiponectin concentrations range
from 3 to 30 pg/rnl and are decreased in
patients with obesity (5), non-insulin-
dependent diabetes mellitus (33), insulin
resistance (75) and dyslipidemia (46). The
incidence of cardiovascular death was
higher in patients with low plasma
adiponectin compared with those with
higher adiponectin levels (81). Decreased
plasma adiponectin concentrations have
been suggested as an indicator of microan-
giopathy in type 2 diabetic patients (33).
The degree of hypoadiponectinemia cor-
related with the incidence of fatal heart
ischemia in the subjects with chronic heart
failure (81). Furthermore, it has been
recently published that male patients with
hypoadiponectinemia «4.0 ug/ml) had a
significant 2-fold increase in coronary
artery disease prevalence, independent of
o.ther well-known coronary artery disease
risk factors (40). These findings suggest
that. t?e measurement of the adipocyte-
specific plasma protein adiponectin level
could be helpful to evaluate coronary
artery disease risk. Therefore, understand-
ing the clinical significance of plasma
adiponectin may be helpful in preventing
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Table I. Factors secreted by adipose tissue.
Factor
Acylation stimulating protein (ASP)
Adiponectin
Adipsin
Agouti
Angiotensinogen
Insulin-like growth factor-1 (IGF-1)
Interleukin-6 (IL-6)
Leptin
Plasminogen activator inhibitor (PAI-1)
Prostaglandin E2 (PGE2)
Prostaglandin b (PGI2)
Sex steroids
Transforming growth factor ~ (fGF~)
Tumor necrosis factor (fNFa)
Vascular endothelial growth factor (VEGF)
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the development of atherosclerotic vascu-
lar diseases.
It is known that plasma adiponectin
rapidly accumulates in the subendothelial
space of the injured human artery (53, 56).
In cultured cells, human recombinant
adiponectin suppressed the attachment of
monocytes to endothelial cells and the
transformation of macrophages to form
cells (55, 56, 57). Besides, adiponectin
dose-dependently inhibits TNF-u sig-
nalling pathway in human aortic endothe-
lial cells as well as it reduces TNF-u pro-
duction in macrophages (53, 77). Recent-
ly, it has been described that adiponectin
acts as a platelet-derived growth factor-
BB-binding protein and generally inhibits
growth factor-induced proliferation and
migration of vascular smooth muscle cells
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(4). Adiponectin concentrations on
human plasma have been directly related
to HDL cholesterol levels and inversely
related to von Willebrand factor levels
(81). Altogether, these facts suggest the
hypothesis that adiponectin acts as a pro-
tective factor for the cardiovascular sys-
tem. Furthermore, it has been recently
documented for the first time that elevat-
ed plasma adiponectin suppresses the
development of atherosclerosis in vivo in
apolipoprotein E-deficient mice (54).
Leptin
Leptin, the peptide product of the ob
gene was discovered in 1994 and it is
secreted mainly by adipocytes (80). Lep-
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tin, a 167-amino acid polypeptide with a
putative 21-amino acid signal sequence
giving rise to a 146-aminoacid secreted
polypeptide, acts through its specific
receptors that exhibit an almost universal
distribution (71). Leptin receptors exist in
at least 6 isoforms. The so called "long
form", OB-Rb, with one transmembrane
domain and a long intracellular carboxy
terminal tail, is thought to be the most
important for transmitting the leptin sig-
nal in cells (1,26, 71). The OB-Ra, OB-
Rc, OB-Rd and OB-Rf are prematurely
terminated receptor proteins with short
intracellular tails, and they are presumed
to facilitate the transport of leptin across
the brain-blood barrier. The OB-Re lacks
the transmembrane domain and, there-
fore, it may function as a soluble receptor
to bind and inactivate circulating leptin
(41). Leptin receptors are found in a vari-
ety of tissues, but OB-Rb is located pre-
dominantly in the hypothalamus.
Leptin is a lipostatic hormone that is
released from adipose tissue and regulates
the amount of body fat by reducing food
intake and increasing energy expenditure
through its action on the hypothalamus
(11, 79). However, elevated serum leptin
levels due to mutations in the leptin gene
or with leptin resistance from mutations
in the leptin receptor, are associated with
profound obesity (45).
The results of recent studies have
shown that leptin is not only a satiety hor-
mone, but is also involved in the regula-
tion of a number of very different physio-
logical processes, such as reproduction
and puberty (73), osteogenesis (72),
hematopoiesis (18), angiogenesis (67), and
regulation of blood pressure (39). Both
clinical and experimental evidence sup-
ports the participation of leptin in blood
pressure regulation. It has been shown
that intracerebroventricular injection or
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chronic intravenous infusion of leptin
increases peripheral resistance and blood
pressure in normotensive rats (14, 65).
These cardiovascular effects of leptin are
at least partially mediated by stimulation
of the sympathetic nervous system (31).
Transgenic mice overexpressing leptin are
characterised by hyperleptinemia, elevat-
ed blood pressure and sympathetic nerve
hyperactivity (2). Although chronic
effects of leptin seem to be predominantly
prohypertensive (65), the fact that leptin
did not acutely increase arterial pressure
despite sympathetic activation suggested
that it may activate counterregulatory
mechanisms (31).
There are several arguments to suggest
that leptin may decrease blood pressure.
First, the role of this adipocyte-derived
peptide on the vascular wall is evident
since the presence of leptin receptors has
been demonstrated in endothelial cells
(67). Leptin is able to increase the produc-
tion of endothelial nitric oxide in isolated
blood vessels and, consequently to induce
direct vasodilation through distinct
endothelial mechanism (28, 42) that
opposes the sympathetic-mediated pres-
sor response (31). We and others have
described the presence of leptin receptors
in vascular smooth muscle cells (VSMCs)
homogenates obtained from aorta of Wis-
tar rats (24, 52). Second, the functionality
of the leptin receptor was previously
demonstrated in calcifying vascular cell
(58) and aortic smooth muscle cells, in
which leptin stimulates the cellular prolif-
eration (52). On the basis of this finding,
there are some recently emerging mecha-
nisms that imply a closer relationship with
the direct action of the vasoactive agonists
on VSMCs. Among them, angiotensin
(Ang) II (12) deserves particular attention
because the renin-angiotensin-aldos-
terone system plays a major role in the
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pathophysiology of hypertension and
related sequelae, such as cardiac hypertro-
phy, diastolic dysfunction, and heart fail-
ure. We recently proposed the hypothesis
that leptin may present another vasodilat-
ing effect by interfering with the vascular
responses induced by Ang II through
OB-Rb. Our experiments have shown
that physiological concentrations of leptin
were able to specifically inhibit the Ang
II-induced fast contraction in endotheli-
um-denuded aortic rings from Wistar rats
(24). This physiological effect was mediat-
ed by a classical intracellular mechanism
of action. We observed that although no
effect of leptin on basal intracellular free
calcium concentration ([Ca2+] i) was
observed, leptin was able to inhibit Ang
II-induced calcium release from intracel-
lular stores in cultured VSMCs of the
aorta from Wistar rats (Fig. 1). Moreover,
the same experiments were repeated on
vascular preparations obtained from
Zucker rats, with a mutation in the leptin
receptor gene that results in the loss of its
functional activity. In these conditions, a
lack of effect of leptin on Ang Il-rnediat-
ed effects was observed. These results sug-
gest that OB-Rb are functional in the vas-
cular wall of Wistar rats and provides a
potential mechanistic explanation for obe-
sity-associated hypertension (24). Togeth-
er these results support the hypothesis
that leptin plays a relevant role in modu-
lating vasoregulatory function directly
through OB-Rb on the different cellular
types of the vascular wall. Finally, it has
also been shown that leptin induces natri-
uresis and diuresis by acting locally in the
rat kidney (37) and it is able to increase
insulin sensitivity in the whole body (68).
Both peripheral mechanisms may also
contribute to the antihypertensive action
of leptin.
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Fig. 1. Effect of different concentrations of leptin on
10-7 molll Ang II -induced changes of tension of
endothelium-denuded aortic rings (A) and in intra-
cellular calcium concentration ([Ca2+Ji) of vascular
smooth muscle cells (VSMCs) (B) from adult Wistar
rats.
Aortic rings were preincubated for 30 min and
VSMCs for 10 min with different concentrations
of leptin. Values are the mean ± SEM from 10-15
determinations/concentration. ", P< 0.05; "", P <
0.01 vs control response to ANG II (Adapted from
reference 24).
Conclusions
Obesity is a common background of
the typical life style-related diseases, such
as hypertension, although the mechanisms
that link obesity with high blood pressure
have not been elucidated. In this sense,
adipose cells seem to playa more dynam-
ic role than previously recognised in
physiological mechanisms. There IS
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already considerable evidence linking
increased production of some adipocyte
factors with the metabolic and cardiovas-
cular complications of obesity. A signifi-
cant inverse relationship between plasma
adiponectin and leptin concentration has
been recently described. While plasma
adiponectin level was decreased in obesity
(5), elevated plasma leptin levels and
adipocyte ob mRNA expression are
strongly correlated with estimates of obe-
sity (1, 47). The inversely related plasma
levels of both adipokines suggest that
both proteins have complementary and/or
opposite roles on fat metabolism, energy
balance, vascular tone and insulin sensitiv-
ity (47, 81). Whether hypoadiponectine-
mia and hyperleptinemia may work
together to accelerate the development of
the cardiovascular pathologies merits fur-
ther investigation.
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La obesidad es la mas cormin de las enfer-
medades nutricionales de los paises industriali-
zados y esta asociada con un aumento de la
mortalidad y morbilidad cardiovascular. Sin
embargo, las bases moleculares de esta asocia-
ci6n aun no se han clarificado. Recientes avan-
ces en la biologia del tejido adiposo han perrni-
tido demostrar que adernas de almacenar ener-
gia, es tam bien un 6rgano de secreci6n capaz
de producir una amplia variedad de sustancias
bioactivas entre las que se incluyen la leptina y
la adiponectina. Ambas hormonas pueden
influir tanto en la funci6n como en la integri-
dad estructural del sistema cardiovascular. La
J. Physiol. Biochem., 59 (1), 2003
leptina, adernas de ser una serial de saciedad
para el sistema nervioso central y estar relacio-
nada con el metabolismo de la glucosa y de la
insulina, desempefia tarnbien un papel en la
regulaci6n del tono vascular, como consecuen-
cia de la amplia distribuci6n de sus receptores
funcionales en las celulas vasculares. Por otra
parte, la adiponectina, proteina descrita mas
recientemente, parece jugar un papel protector
en los modelos experimentales de dafio vascu-
lar, en parte, porque es capaz de suprimir la
uni6n de los monocitos a las celulas endotelia-
les, que es un paso fundamental en el proceso
ateroscler6tico. Existen suficientes evidencias
que relacionan alteraciones de laproducci6n de
hormonas adipocitarias con las complicaciones
cardiovasculares de la obesidad. En consecuen-
cia, el avance en el conocimiento de las altera-
ciones en la funci6n endocrina del tejido adi-
poso podria ayudar a entender el riesgo cardio-
vascular asociado a la obesidad.
Palabras clave:Adipocitos, Adiponectina, Enfer-
medades cardiovasculares, Leptina, Obesidad.
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